New Tools for Coronary Risk Assessment
- 19 February 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (7) , 886-892
- https://doi.org/10.1161/hc0702.103727
Abstract
The concept of risk assessment and reduction, introduced initially by the Framingham Heart Study and refined in other models, forms the cornerstone of preventive cardiology. Risk factor assessment determines the therapeutic strategy, because the intensity of preventive intervention is tailored to the patient’s risk of coronary heart disease. The conventional risk factors for coronary heart disease include elevated serum total cholesterol and LDL cholesterol, low HDL cholesterol, elevated blood pressure, cigarette smoking, diabetes, vascular disease, menopausal status (women only), and age. Aggressive risk factor reduction, formerly used exclusively in secondary prevention, may be pivotal to optimal patient management in high-risk primary prevention. A number of noninvasive imaging modalities have the potential to measure and to monitor atherosclerosis in asymptomatic individuals and include exercise ECG testing, electron beam computed tomography, magnetic resonance coronary angiography, positron emission tomography, ankle-brachial index, and B-mode ultrasound. Novel serum markers, including C-reactive protein and homocysteine, have the ability to gauge risk in the individual patient. Systemic therapy for risk reduction in primary prevention may be preferable to local therapy (eg, angioplasty and bypass) and may more effectively prevent acute coronary events than these more invasive approaches.Keywords
This publication has 25 references indexed in Scilit:
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Primary Prevention of Coronary Heart Disease in Women through Diet and LifestyleNew England Journal of Medicine, 2000
- DiscussionThe American Journal of Cardiology, 1999
- Effect of HMG-CoA Reductase Inhibitors on Coronary Artery Disease as Assessed by Electron-Beam Computed TomographyNew England Journal of Medicine, 1998
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2Atherosclerosis, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Elucidation off the role of plaque instability and rupture in acute coronary eventsThe American Journal of Cardiology, 1995
- Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple risk factor intervention trial experienceJournal of the American College of Cardiology, 1986
- Value of maximal exercise tests in risk assessment of primary coronary heart disease events in healthy men: Five years' experience of the seattle heart watch studyThe American Journal of Cardiology, 1980